/ Not yet recruitingNot Applicable A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Seven Arm, Four-Period Cross-over, Incomplete Block Design, 7-Day Dosing Study to Assess the Dose-Response, Safety, and Efficacy of EP-101 in Subjects with Moderate to Severe COPD
100 Clinical Results associated with Elevation Pharmaceuticals, Inc.
0 Patents (Medical) associated with Elevation Pharmaceuticals, Inc.
100 Deals associated with Elevation Pharmaceuticals, Inc.
100 Translational Medicine associated with Elevation Pharmaceuticals, Inc.